Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency-Reference-Cited by-同舟云学术

Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency

Published:2016-11-22 Issue:4 Volume:54 Page:241-247
ISSN:0022-2593
Container-title:Journal of Medical Genetics
language:en
Short-container-title:J Med Genet

Author:

Yang Hao,Al-Hertani Walla^ORCID,Cyr Denis,Laframboise Rachel,Parizeault Guy,Wang Shu Pei,Rossignol Francis,Berthier Marie-Thérèse,Giguère Yves,Waters Paula J,Mitchell Grant A

Publisher

BMJ

Subject

Genetics (clinical),Genetics

Reference34 articles.

1. Recommendations for the management of tyrosinaemia type 1;de Laet;Orphanet J Rare Dis,2013

2. Tyrosinemia: a review;Russo;Pediatr Dev Pathol,2001

3. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots;Allard;Clin Biochem,2004

4. Newborn screening: toward a uniform screening panel and system–executive summary;Watson;Pediatrics,2006

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1;GENETICS;2024-08-23

2. New Cases of Maleylacetoacetate Isomerase Deficiency with Detection by Newborn Screening and Natural History over 32 Years: Experience from a German Newborn Screening Center;International Journal of Neonatal Screening;2024-02-27

3. Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation;Canadian Liver Journal;2024-02-26

4. Clinical physiology and pharmacology of GSTZ1/MAAI;Biochemical Pharmacology;2023-11

5. In vivodissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1;2023-09-29